How to Submit an Application
Applications will not be considered until all relevant information for the review is complete. A complete application includes:
- The appropriate application form
- Consent Forms (as necessary)
- All supplemental material (e.g., questionnaires and other assessment tools)
- The most recent investigators brochure for clinical trials
- The allocated budget
- Any other relevant correspondence
In addition, other supplemental material necessary for the decision process should be provided before the review. Such supplemental material may include advertisements for recruitment, preclinical information from animal studies depending on the phase of the clinical trial, and any correspondence from other sources that might be pertinent to the review (such as the details from any other ethical reviews that have been carried out by other Boards).
The primary cause of delay in ethics approval is incomplete information.
Please consult the information below for specific information on different types of submissions:
All submissions must be received by the REB through the Coordinated Approval Process for Clinical Research (CAPCR) system.
Amendments, Renewals, Terminations, Unanticipated Problem Reports
- Emailed to email@example.com
- Subject Line: “UHN REB # xx-xxx-xx – Dr. X – Amendment/Renewal/Temination/Unanticipated Problem Report" (i.e. UHN REB # 12-3456-AB – Dr. Doe – Amendment)
- Attachments: All required documents (signed* and completed forms, tracked and clean copies of any already-approved documents that have been changed, other information, etc.)
*Signatures in forms are NOT required, if the completed form is being sent from the PI’s UHN email
Where to Submit
All non-CAPCR (Amendments, Renewals, Terminations, Unanticipated Problem Reports) submissions should be sent to firstname.lastname@example.org
If the e-mail submission is too large and your mail client refuses to send the submission, please attach documents to the UHN Research File Portal
(Please note that this option is only available to you if you have access to the UHN Intranet)
Delegated Review for Access to Retrospective Patient Data: Research Requests - Oncology
Oncology Research requests must be submitted to the PMH Cancer Registry Data Access Committee (CRDAC) for approval prior to review by the UHN REB. Once CRDAC has approved the application, CRDAC will notify the Principal Investigator of the approval and will forward the PI a notification of approval letter. CRDAC will notify the REB of approval and will forward the original application to the REB office for review. Once approved by the REB, an REB notification of approval letter will be mailed to the PI.
Please contact CRDAC for more information.
I want to start my research project ASAP. What can I do?
Note that the primary cause of delay in ethics approval is incomplete information. Be sure to provide copies of all supplemental material necessary for the decision process: e.g. — advertisements for recruitment, preclinical information from animal studies (depending on the phase of the clinical trial), and any correspondence from other sources that might be pertinent to the review.